NC
MDGL icon

NinePointTwo Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

NinePointTwo Capital’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-984
Closed -$227K – 290
2023
Q2 		$227K Buy
+984
New +$267K 0.09% 173

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

NinePointTwo Capital's MDGL Position: Q3 2023 in Review

NinePointTwo Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2023, closing a stake of 984 shares — an estimated $227K sold.

NinePointTwo Capital first reported a position in MDGL in Q2 2023 and held it in 1 quarter. The position peaked at $227K in Q2 2023. 205 funds tracked by Wall St. Rank hold MDGL as of Q3 2023.

  • NinePointTwo Capital reported no remaining Madrigal Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • NinePointTwo Capital sold 984 Madrigal Pharmaceuticals shares in Q3 2023, an estimated $227K.
  • NinePointTwo Capital first reported a position in Madrigal Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • NinePointTwo Capital's Madrigal Pharmaceuticals position peaked at $227K in Q2 2023.
  • 205 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2023.

Based on NinePointTwo Capital's 13F filing for Q3 2023, filed 14 Nov 2023.